ODDO BHF ASSET MANAGEMENT SAS
Position in ALNY — Alnylam Pharmaceuticals, Inc.
CIK 1686970
PARIS, I0
Position in ALNY
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$3,333,606
-$7,589,405 QoQ
Shares Held
11,074
-66.5% QoQ
Ownership
0.008%
of shares outstanding
% of Portfolio
0.18%
of 13F equity value
Holder Rank
#269
of 784 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ALNY Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ODDO BHF ASSET MANAGEMENT SAS holds $77,360,522 across 7 Biotechnology names. ALNY ranks #5 (4.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ASND |
Ascendis Pharma A/S
|
128,657 | $34,315,395 | |
| 2 | ARGX |
Argenx SE
|
25,009 | $23,202,599 | |
| 3 | ABVX |
Abivax S.A.
|
81,496 | $10,860,156 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
10,151 | $5,042,306 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
This page
|
11,074 | $3,333,606 | |
| 6 | RNA |
Atrium Therapeutics, Inc.
|
45,090 | $606,460 | |
| 7 | 227,386 | $0 |
All Filings in ALNY
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,333,606 | 11,074 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $10,923,011 | 33,013 | Shares | Sole | 2026-05-18 | |
| 2025-12-31 | $11,982,387 | 30,133 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $17,294,712 | 37,927 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $11,719,674 | 35,940 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $5,352,066 | 19,821 | Shares | Sole | 2025-05-12 | |
| No filing history on record for this holder in this stock. | ||||||